Single-Agent Tislelizumab, an Anti-PD-1 Antibody: Results from a Phase 1 Expansion Cohort in NSCLC Patients

被引：1
|
作者：
Barlow, P. [1 ]
Jameson, M. [2 ,3 ]
Lin, C. [4 ]
Wu, J. [5 ]
Pirzkall, A. [5 ]
Lee, J. [6 ]
机构：
[1] Auckland City Hosp, Auckland, New Zealand
[2] Waikato Hosp, Reg Canc Ctr, Hamilton, New Zealand
[3] Univ Auckland, Waikato Clin Campus, Hamilton, New Zealand
[4] Natl Taiwan Univ Hosp, Taipei, Taiwan
[5] Beigene Usa Inc, San Mateo, CA USA
[6] Seoul Natl Univ, Bundang Hosp, Seongnam Si, Gyeonggi Do, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
tislelizumab; NSCLC; Anti-PD-1;
D O I：
10.1016/j.jtho.2019.08.1538
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-33
引用
收藏
页码：S721 / S721
页数：1
相关论文
共 50 条
  • [41] Neoantigen Targeting in NSCLC Patients with Complete Response to Anti-PD-1 Immunotherapy
    Smith, Kellie
    Anagnostou, Valsamo
    Forde, Patrick
    Brahmer, Julie
    Velculescu, Victor
    Pardoll, Drew
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S322 - S323
  • [42] Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1
    Robert, Caroline
    Lebbe, Celeste
    Lesimple, Thierry
    Lundstrom, Eija
    Nicolas, Valerie
    Gavillet, Bruno
    Crompton, Philippa
    Baroudjian, Barouyr
    Routier, Emilie
    Lejeune, Ferdy J.
    CLINICAL CANCER RESEARCH, 2023, 29 (05) : 858 - 865
  • [43] Efficacy of anti-PD-1 antibodies in NSCLC patients with anEGFRmutation and high PD-L1 expression
    Masuda, Ken
    Horinouchi, Hidehito
    Tanaka, Midori
    Higashiyama, Ryoko
    Shinno, Yuki
    Sato, Jun
    Matsumoto, Yuji
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Yamamoto, Noboru
    Ohe, Yuichiro
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (01) : 245 - 251
  • [44] Operability changes in patients with NSCLC after neoadjuvant chemotherapy and anti-PD-1/PD-L1
    Garitaonaindia, Yago
    Baena Espinar, Javier
    Aguado, Carlos
    Cruz, Patricia
    Lopez Castro, Rafael
    Rubio, Jaime
    Gomez, Ana
    Lopez Martin, Ana
    Traseira, Cristina
    Mielgo Rubio, Xabier
    Losada, Beatriz
    Rogado Revuelta, Jacobo
    Romano, Irene
    Luis Campo-Canaveral, Jose
    Gomez de Antonio, David
    Falagan, Sandra
    Rubio, Gustavo
    Javier Montoro, Francisco
    Sereno, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Interim results of a phase 1/2 study of JNJ-63723283, an anti-PD-1 monoclonal antibody, in patients with advanced cancers.
    Calvo, Emiliano
    Moreno, Victor
    Felip, Enriqueta
    Curigliano, Giuseppe
    Morgensztern, Daniel
    Greger, James
    Bae, Kyounghwa
    Mayer, Christina Lourdes
    Marino, Jennifer
    Attiyeh, Edward F.
    Xie, Hong
    Lee, James J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [46] Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)
    Moreno, V.
    Gil-Martin, M.
    Johnson, M.
    Aljumaily, R.
    Lopez Criado, P.
    Northfelt, D. W.
    Crittenden, M.
    Jabbour, S.
    Rosen, L.
    Garrido Lopez, P.
    Hervas Moron, A.
    Rietschel, P.
    Mohan, K. K.
    Li, J.
    Stankevich, E.
    Rowlands, T.
    Feng, M.
    Lowy, I.
    Fury, M. G.
    ANNALS OF ONCOLOGY, 2018, 29 : 414 - 414
  • [47] Defining melanoma patients unresponsive to single agent anti-PD-1 therapy but responsive to combination anti-PD-1+anti-CTLA-4 therapy
    Edwards, Jarem J.
    da Silva, Ines Pires
    Ferguson, Angela
    Johansson, Peter
    Conway, Jordan
    Attrill, Grace
    Saw, Robyn P. M.
    Thompson, John F.
    Menzies, Alexander M.
    Palendira, Umaimainthan
    Long, Georgina, V
    Scolyer, Richard A.
    Wilmott, James S.
    CANCER RESEARCH, 2020, 80 (16)
  • [48] Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)
    Moreno, V.
    Gil-Martin, M.
    Johnson, M. L.
    Aljumaily, R.
    Criado, P. Lopez
    Northfelt, D. W.
    Crittenden, M.
    Jabbour, S.
    Rosen, L.
    Garrido, P.
    Moron, A. Hervas
    Rietschel, P.
    Mohan, K. K.
    Li, J.
    Stankevich, E.
    Feng, M.
    Lowy, I.
    Fury, M. G.
    ANNALS OF ONCOLOGY, 2018, 29 : 26 - 26
  • [49] Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies
    Gong, Jifang
    Liu, Chang
    Yao, Jun
    Xue, Junli
    Dai, Jing
    Ji, Yinghua
    Markman, Ben
    Hiong, Alison
    Yang, Xiuli
    Zhao, Rusen
    Zheng, Yi
    Li, Qingshan
    Wu, Jun
    Barve, Minal A.
    Ariyapperuma, Mihitha Hashara
    Richardson, Gary Edward
    Qin, Xia
    Qin, Crystal Ying
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Tislelizumab, an investigational anti-PD-1 antibody, combined with chemotherapy as first-line treatment for lung cancer in Chinese patients.
    Wang, Jie
    Zhao, Jun
    Wang, Zhijie
    Ma, Zhiyong
    Cui, Jiuwei
    Shu, Yonggian
    Liu, Zhe
    Cheng, Ying
    Leaw, Shiangjin
    Xia, Fan
    Wu, Yanjie
    Liang, Liang
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345